WEP CLINICAL EXPANDS AVAILABILITY OF XENLETA® (LEFAMULIN) NAMED PATIENT PROGRAM IN PARTNERSHIP WITH NABRIVA THERAPEUTICS
WEP Clinical (WEP) and Nabriva Therapeutics (Nabriva) are pleased [...]
WEP CLINICAL EXTENDS PARTNERSHIP WITH BTG SPECIALTY PHARMACEUTICALS BY GAINING WORLDWIDE (EX-US) DISTRIBUTION RIGHTS FOR DIGIFAB®
WEP Clinical (WEP) announced today that it has extended [...]
WEP CLINICAL PARTNERS WITH US BIOTECH COMPANY FOR THE NAMED PATIENT SUPPLY OF CANCER PRODUCT IN EX-US COUNTRIES
WEP Clinical (WEP) announced today that, as of July [...]
WEP CLINICAL PARTNERS WITH BTG SPECIALTY PHARMACEUTICALS FOR EUROPEAN SUPPLY OF VORAXAZE®
WEP Clinical (WEP) announced today that it has entered [...]
WEP CLINICAL PARTNERS WITH NABRIVA THERAPEUTICS FOR THE NAMED PATIENT SUPPLY OF XENLETA® (LEFAMULIN)
WEP Clinical (WEP), a specialist pharmaceutical services company, has [...]
WEP CLINICAL JOINS WITH WREN HEALTHCARE TO PROVIDE HOME HEALTHCARE SERVICES
WEP Group Holdings Limited (WEP), a specialist CRO focused [...]
WEP CLINICAL PARTNERS WITH MYLAN TO PROVIDE PRODUCT FOR HIGHLY DRUG-RESISTANT TUBERCULOSIS
WEP Clinical (WEP), the specialist pharmaceutical services company, has [...]
WEP CLINICAL LAUNCHES COVID-19 ANTIBODY TESTING SERVICE
WEP Clinical (WEP), the specialist pharmaceutical services company, is [...]
CORONAVIRUS STATEMENT – 16 MARCH 2020
WEP Clinical (“WEP”)’s management team met on 16 March [...]
WEP CLINICAL AND WELLSTAT THERAPEUTICS CORPORATION ENTER INTO NEW PARTNERSHIP FOR THE NAMED PATIENT SUPPLY OF VISTOGARD® (URIDINE TRIACETATE)
WEP Clinical, the specialist pharmaceutical services company, announces that [...]